Clinical Trials
72 trialsNCT00690560 2026-05-22
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Centre Antoine Lacassagne
Phase 2 Completed
NCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT03943901 2026-01-29
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00911183 2025-08-29
FRAIL-06
Institut Bergonié
Phase 2 Completed
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01359592 2025-06-17
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT00670358 2025-01-10
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT02529852 2024-09-19
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00101101 2023-08-22
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00039130 2023-08-21
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01399372 2023-07-20
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00335140 2023-07-03
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00003389 2023-06-29
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00060346 2023-06-29
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00274924 2023-06-29
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00217425 2023-06-18
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated
NCT00822120 2022-08-18
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00069238 2022-02-24
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00070018 2022-01-11
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed
NCT01445535 2021-11-03
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01412879 2021-10-29
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00299182 2021-09-21
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00051311 2021-09-09
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00004031 2021-02-02
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT00671658 2020-12-03
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00577993 2020-11-16
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00058422 2020-11-12
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00101010 2020-10-19
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00290433 2020-09-23
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01889069 2020-08-13
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Hoffmann-La Roche
Phase 3 Completed
NCT00451178 2020-07-21
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
Eli Lilly and Company
Phase 2 Completed
NCT00290498 2020-06-02
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00392990 2019-10-15
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
Northwestern University
Phase 2 Completed
NCT00301821 2019-10-09
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00770224 2019-08-28
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00004228 2019-08-06
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00809341 2018-09-25
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00133991 2018-09-17
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed